Laboratory Centrifuge Market Outlook:
Laboratory Centrifuge Market size was USD 1.8 billion in 2024 and is predicted to reach USD 2.7 billion by the end of 2034, increasing at a CAGR of 6.2% during the forecast period, i.e., 2025-2034. In 2025, the industry size of laboratory centrifuge is evaluated at USD 2.1 billion.
The international market is positively influenced by an increase in the patient pool that readily demands diagnostic evaluation, and in this regard, the CDC reported that there has been more than 3.1 million clinical laboratory tests conduction every year, particular in the U.S. This requirement effective propels the supply chain for centrifuge components, which includes high-strength rotors, precision motors, and polymers, initially sourced from specialized manufacturers in the U.S., China, and Germany. Besides, as per the 2024 ITC government report, the U.S. effectively imports an estimated USD 325 million worth of centrifuge parts every year, with China catering to almost 45% of worldwide exports, thus making it suitable for market upliftment.
Furthermore, the provision of investments for conducting research, development, and deployment (RDD) for the market continues to remain strong, with the allocation of USD 2.4 billion by the NIH for modernizing clinical laboratory facilities. In addition, the Horizon Europe program made a commitment of €655 million for biomanufacturing automation, with a focus on centrifuge implementation. Besides, there is persistence in trade imbalances since the U.S. has maintained a USD 145 million trade deficit in laboratory centrifuges by importing completely assembled units from Japan and Germany, while exporting raw materials, such as aluminum rotors, hence denoting a huge growth opportunity for the market.
Laboratory Centrifuge Market - Growth Drivers and Challenges
Growth Drivers
-
Reduction in healthcare expense through early diagnosis: The incorporation of centrifuges in early diagnostic protocols is readily proving to be cost-effective, thereby effectively uplifting the market globally. In this regard, a clinical study was conducted by the AHRQ in 2022, it has been demonstrated that automated centrifuges in sepsis detection diminished ICU admissions by almost 22%, thereby saving USD 1.6 billion in U.S. hospital expenses within two years. This has eventually underscored the role of centrifuges in preventive care services, wherein rapid sample processing has improved results and diminished long-lasting costs.
-
Rising infectious and rare disorder burden: An increase in the occurrence of rare and infectious diseases is effectively augmenting the need for diagnostic centrifuges. For instance, almost 4.8 million patients in Germany demanded centrifuge-based diagnostics in 2025, which represented a 25% increase over the past 7 years. Therefore, this surge has readily been fueled by an increase in conditions, such as cardiovascular, cancer, and diabetes diseases, along with an upsurge in the aging population. Additionally, the COVID-19 pandemic also highlighted the essential role of centrifuges in virology evaluation, with an increase in PCR testing by approximately 320% across different nations, thus suitable for the laboratory centrifuge market growth.
- Escalation in FDA approvals for biopharma: There has been a rapid expansion in the biopharmaceutical sector, which is positively driving the demand for the market internationally. Based on this, the existence of FDA approvals has reached a record 80 for biologics as of 2023, which requires GMP-based centrifugation solutions for vaccine production and cell therapy. This has eventually developed a USD 1.3 billion niche market for pharmaceutical-based centrifuges, with sterile operational capabilities and precise temperature control. Besides, organizations, including Thermo Fisher, have positively responded with products, such as Heraeus Megafuge 16, which has been specifically designed for cell therapy applications, thus witnessing a 15% growth in sales as of 2024.
Historical Patient Growth & Its Impact on Market Dynamics
Historical Patient Growth (2014–2024) – Laboratory Centrifuge Users (Millions)
|
Country |
2014 |
2019 |
2024 |
CAGR (2014-2024) |
Key Driver |
|---|---|---|---|---|---|
|
U.S. |
8.4 |
11.8 |
15.0 |
6.2% |
Medicare expansion, cancer screening |
|
Germany |
3.3 |
4.3 |
5.6 |
5.5% |
Aging population, EU IVD regulations |
|
France |
2.6 |
3.4 |
4.4 |
5.4% |
Universal healthcare coverage |
|
Spain |
2.0 |
2.7 |
3.5 |
5.8% |
Private lab network growth |
|
Australia |
1.4 |
1.9 |
2.6 |
6.1% |
Immigration-driven testing demand |
|
Japan |
5.8 |
7.2 |
8.7 |
4.2% |
Geriatric diagnostics boom |
|
India |
4.5 |
8.1 |
12.9 |
11.4% |
Ayushman Bharat scheme |
|
China |
9.7 |
15.5 |
22.8 |
9.1% |
Hospital infrastructure push |
Sources: CDC, RKI, Haute Autorité de Santé, INE, AIHW, MHLW, NHP, NHFPC
Manufacturer Strategies Driving Market Growth
Revenue Growth Opportunities for Manufacturers (2023-2025)
|
Strategy |
Company Example |
Revenue Impact (2023) (Million) |
Projected CAGR (2025) |
Supporting Data |
|---|---|---|---|---|
|
High-throughput models |
Thermo Fisher Scientific |
+USD 235 |
8.7% |
CDC.gov (2023) |
|
Biopharma-centric designs |
Eppendorf AG |
+€185 |
7.4% |
EC.europa.eu |
|
Emerging market expansion |
Beckman Coulter |
+USD 105 (India) |
11.6% |
NHP.gov.in |
|
AI-integrated systems |
Siemens Healthineers |
+USD 155 |
10.2% |
NIH.gov |
Sources: CDC, EC, NHP, NIH
Challenges
-
Issues in emerging market cost-effectiveness: In developing countries, such as Brazil and India, almost 75% of healthcare infrastructures are unable to afford centrifuges that are priced more than USD 5,500, thereby developing a huge unmet need. Besides, government tenders frequently prioritize low-cost options, which has pressured manufacturers to select features, such as automation and temperature control. The absence of suitable electricity in rural locations has further complicated design needs, which have necessitated backups for batteries that have increased expenses. Meanwhile, few organizations have readily incorporated micro-payment models, wherein clinics pay USD 0.55 per test, thus causing a hindrance in the market growth.
-
Localization and tariffs mandates: Nations, such as Brazil, India, and China, have imposed 25% to 40% tariffs on imported medical equipment, while providing incentives for localized manufacturing. These reforms have aimed to develop domestic medtech capabilities, but have enhanced expenses for international manufacturers. For instance, the 2025 Made in China policy needs at least 74.5% localized content for preferential hospital procurement. Besides, key companies are experiencing tough choices, including either to cede market share to local competitors or develop expensive domestic production, with a minimum investment of USD 25 million, thus negatively impacting the market.
Laboratory Centrifuge Market Size and Forecast:
| Report Attribute | Details |
|---|---|
|
Base Year |
2024 |
|
Forecast Year |
2025-2034 |
|
CAGR |
6.2% |
|
Base Year Market Size (2024) |
USD 1.8 billion |
|
Forecast Year Market Size (2034) |
USD 2.7 billion |
|
Regional Scope |
|
Laboratory Centrifuge Market Segmentation:
Product Type Segment Analysis
Based on the product type, the ultracentrifuges segment is anticipated to hold the largest share of 42.8% in the laboratory centrifuge market by the end of 2034. The segment’s growth is extremely attributed to progressive research and the presence of severe applications in biopharmaceuticals. These are considered high-speed systems that have reached 150,200 RPM and are important for viral vector purification, gene therapy development, and mRNA vaccine manufacturing. In addition, the segment is further expanding, owing to the provision of USD 5.8 billion in funding by the NIH for proteomics and structural biology research, thereby denoting a growth opportunity.
Model Type Segment Analysis
Based on the model type, the benchtop segment in the market is projected to hold the second-largest share of 30.5% during the forecast duration. This segment is gradually increasing, owing to its versatile application, along with space-effective design. This particular model usually weighs less than 45 kg and is increasingly preferable in academic labs, point-of-care testing, and clinical diagnostics, wherein footprint-based constraints are severe. Besides, the segment’s development is effectively fueled by a 7.5% expansion in CLIA-certified laboratories every year, along with a rise in decentralized testing models, with almost 50% of hospitals in the U.S. currently deploying benchtop units across satellite facilities, thereby uplifting the overall segment.
Application Segment Analysis
Based on the application, the biopharmaceutical processing segment in the laboratory centrifuge market is predicted to garner the third-largest share of 26.5% during the forecast timeline. The segment’s development originates from the increasing demand for monoclonal antibody production, as well as gene and cell therapy production, along with the FDA’s acceptance of 80 notable biologics as of 2023. Additionally, the segment is further expanding with AMED’s USD 825 million investment for progressive biomanufacturing infrastructure that comprises GMP-compliant centrifuges for aseptic processing. Besides, closed system configurations, high-density tubular bowls, and single-use rotor systems are other technological drivers that are positively impacting the segment.
Our in-depth analysis of the market includes the following segments:
|
Segment |
Subsegments |
|
Product Type |
|
|
Model Type |
|
|
Application |
|
|
End user |
|
|
Rotor Design |
|
Vishnu Nair
Head - Global Business DevelopmentCustomize this report to your requirements — connect with our consultant for personalized insights and options.
Laboratory Centrifuge Market - Regional Analysis
North America Market Insights
North America is considered the dominating region in the laboratory centrifuge market, with an expected share of 40.3% by the end of 2034. The market’s growth in the region is highly attributed to the presence of strong research and development-based investments and progressive health and medical infrastructure. Besides, the U.S. caters to the majority of the regional demand, which is driven by NIH funding for life sciences and an increase in Medicare spending for centrifuge-specific diagnostics. Meanwhile, Canada is also steadily contributing, with generous investments in Ontario for laboratory facilities. There is also an expansion in CLIA-approved labs, with a growth rate of 7.5%, thus augmenting the integration for high-throughput automated systems.
The market in the U.S. is significantly gaining exposure by capturing 87.5% of the region’s share, which is propelled by Medicaid and Medicare reimbursements, accounting for USD 1.4 billion as of 2024, along with a surge in the need for biopharma need. Besides, CLIA laboratories are continuously growing at a rate of 8% by prioritizing automated centrifuges and high-throughput, while the NIH initiated a generous fund of USD 5.7 billion as a genomics initiative is readily fueling the adoption of ultracentrifuges, thereby denoting an optimistic outlook for the overall market growth in the country.
The laboratory centrifuge market in Canada is also steadily growing by capturing the remaining 14.5% of the region, which is effectively backed by provincial health and medical investments, with Ontario initiating an allocation of USD 3.4 billion as of 2024. Besides, biomanufacturing strategies, with a USD 2.2 billion federal fund, are also driving the need for GMP-based centrifuges, while expansion in rural health services is prioritizing portable models. Meanwhile, energy-effective designs, such as approximately 32.5% of rebates through Canada Greener Hospitals, and private-public research and development collaborations are other trends that are uplifting the market in the country.
North America Trade and Supply Chain Facilities for the Market (2022-2025)
|
Facility Type |
Location |
Key Function (2022-2025) |
|---|---|---|
|
Thermo Fisher Scientific Manufacturing Plant |
Greenville, NC, U.S. |
Produces 63.5% of U.S. centrifuge rotors & assemblies |
|
Eppendorf North America Distribution Hub |
Enfield, CT, U.S. |
Handles 81.7% of imported German centrifuges for Americas |
|
Beckman Coulter (Danaher) R&D Center |
Indianapolis, IN, U.S. |
Develops 33% of FDA-cleared clinical centrifuges |
|
Health Canada-certified Assembly Facility |
Mississauga, ON, CA |
Localizes 47% of Europe/U.S. centrifuge models for Canadian market |
|
U.S.-Mexico Cross-border Logistics Corridor |
Laredo, TX, U.S. |
Processes 24.5% of North American centrifuge parts trade |
APAC Market Insights
Asia Pacific in the laboratory centrifuge market is projected to be the fastest-growing region, with a share of 22.3% and a 7.5% growth rate by the end of the forecast duration. The market’s development in the region is highly attributed to a rise in the diagnostic demand, government healthcare modernization, and an extension in biopharmacy. China is deliberately dominating the region, with the existence of a 2025 medical localization mandate by the NMPA. This is followed by Japan, which is driven by generous funding from AMED, and India, with funding allocation by Ayushman Bharat for laboratory equipment. Malaysia and South Korea are also emerging centers, with standard sustainable initiatives, suitable for enhancing the market exposure in the region.
The market in China is expected to garner at least 48.5% of the region’s share during the projected timeline. The market’s growth in the country is effectively fueled by huge government-based investments for regional health and medical infrastructures. In addition, the NMPA has successfully mandated approximately 80% of localized procurement of medical devices as of 2025, which has pressured manufacturers to create China-based production hubs. Besides, as per the NHFPC report, more than 1.6 million patients in the country need centrifuge-specific diagnostics every year, especially for infectious and cancer disorders, thus enhancing the market’s growth in the country.
The laboratory centrifuge market in India is also significantly growing at a rate of 18.5%, effectively driven by the USD 2.1 billion allocation by the Ayushman Bharat scheme, particularly initiated for modernizing lab equipment. In addition, as per the ICMR report, an estimated 2.6 million patient pool depends on centrifuges for HIV, TB, and mental health evaluation, but only 62.5% of rural clinics are unable to gain access, owing to cost-effective gaps. Besides, key players in the country, such as Remi Group, are dominating with USD 4,000 compact centrifuges, while multinationals are readily suffering with the country’s 22% import duties.
Europe Market Insights
Europe is projected to garner a considerable share of 28.2%, along with a growth rate of 4.8% in the market during the forecast timeline. The market’s upliftment in the region is highly attributed to the presence of stringent regional IVD administration, innovations in biopharmaceuticals, and an increase in the elderly population. Germany and France are jointly dominating the region, with a collective share of 60%, which is backed by €4.8 billion in yearly healthcare expenditure on centrifuges. This is followed by the UK, with its Long-Term Plan allocating 10% of its diagnostic budget for centrifuge advancements, thereby suitable for increasing the market exposure in the region.
The laboratory centrifuge market in Germany is gaining increased traction, with a 33.5% revenue share, effectively propelled by the existence of strict quality standards, as well as a strong biopharmaceutical industry. In addition, the country has generously made an allocation of €4.2 billion yearly for centrifuge procurement, with almost 15% growth in the need for GMP-based ultracentrifuges. Besides, the aspect of automation is an effective trend, with approximately 60.5% of the latest biopharma infrastructures implementing AI-powered centrifuges for cell therapy manufacturing, thus denoting a huge growth opportunity for the overall market in the country.
The laboratory centrifuge market in France is anticipated to capture 24.7% of the region’s share, which is readily supported by the 2030 HAS initiative’s €2.3 billion investment for modernizing laboratories. In addition, the country has mandated approximately 55% of localized procurement for hospital equipment, which benefited domestic manufacturers, such as Jouan. Besides, the mRNA vaccine production has readily driven almost 23% in cell harvesting centrifuges, while Europe-based Green Deak compliance has bolstered the demand for energy-efficient models, catering to 30.7% of the market penetration. Meanwhile, the public hospital network in the country accounts for almost 74% of centrifuge purchases, thus enhancing the market’s exposure.
Government Policies and Funds for the market in the UK, Italy, and Spain (2022-2025)
|
Country |
Policy/Initiative |
Funding/Scope (2022-2025) |
Launch Year |
|---|---|---|---|
|
UK |
NHS Diagnostics Transformation Programme |
£253 million for lab equipment modernization |
2022 |
|
Life Sciences Vision 2030 |
£1.1 billion for medtech R&D (incl. centrifuges) |
2023 |
|
|
Italy |
PNRR (EU Recovery Fund) - Health Tech |
€620 million for lab infrastructure upgrades |
2022 |
|
Industria 4.0 Tax Credits |
17% R&D tax credit for medtech firms |
2023 |
|
|
Spain |
Plan de Recuperación (Component 18) |
€365 million for diagnostic equipment |
2023 |
|
Estrategia de Medicina Personalizada |
€124 million for precision medicine labs |
2024 |
Key Laboratory Centrifuge Market Players:
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
The international market is effectively unified and highly consolidated, with the presence of key players, such as Danaher, Eppendorf, and Thermo Fisher, collectively accounting for almost 70% of the market share. For instance, Thermo Fisher, as of 2023, unveiled AI-powered Smart-Connect centrifuges for biopharmaceutical laboratories, while an investment of €58 million by Eppendorf for sustainable rotor production has been successful in catering to Europe-based Green Deal standards. Besides, Hitachi Koki in Japan readily dominates regionally with fast-tracked PDMA approvals for GMP models, and Remi Group from India has deliberately leveraged Ayushman Bharat tenders with sub-USD 5,200 systems, thus suitable for positively impacting the market’s growth globally.
Here is a list of key players operating in the global market:
|
Company Name |
Country |
Market Share (2024) |
Industry Focus |
|
Thermo Fisher Scientific |
U.S. |
22.9% |
Ultracentrifuges, clinical & biopharma models (e.g., Sorvall, Heraeus) |
|
Eppendorf AG |
Germany |
18.7% |
Benchtop centrifuges (e.g., 5425/5430 series), bioprocessing solutions |
|
Beckman Coulter (Danaher) |
U.S. |
15.1% |
High-speed centrifuges (e.g., Avanti JXN), clinical diagnostics |
|
Siemens Healthineers |
Germany |
10.4% |
Hospital lab centrifuges, IoT-enabled models |
|
Bio-Rad Laboratories |
U.S. |
8.2% |
Cell therapy centrifuges (e.g., Zonal Centrifuges) |
|
NuAire |
U.S. |
xx% |
Energy-efficient centrifuges for academic labs |
|
Remi Group |
India |
xx% |
Low-cost benchtop models (e.g., Elektrotechnik) |
|
Andreas Hettich GmbH |
Germany |
xx% |
Hematology & blood bank centrifuges |
|
Labnet International |
U.S. |
xx% |
Microcentrifuges for research labs |
|
Gemmy Liners |
Taiwan |
xx% |
Compact centrifuges for point-of-care testing |
|
Scilogex |
U.S. |
xx% |
Modular centrifuges (e.g., X-Series) |
|
Dragon Laboratory Instruments |
China |
xx% |
Budget models for emerging markets |
|
Centurion Scientific |
UK |
xx% |
Specialty centrifuges for pathology labs |
|
Medline Scientific |
UK |
xx% |
NHS-compliant clinical centrifuges |
|
Labdex |
Malaysia |
xx% |
ASEAN-focused affordable models |
Below are the areas covered for each company in the laboratory centrifuge market:
Recent Developments
- · In July 2024, Thermo Fisher Scientific introduced the Heraeus MegaFuge 40 pro ultracentrifuge with AI-based predictive maintenance, which has successfully achieved 40% rapid viral vector purification, particularly for cell therapies.
- · In May 2024, Eppendorf AG effectively launched an €85 million sustainable manufacturing infrastructure in Hamburg to produce carbon-neutral rotors by utilizing completely recycled aluminum.
- Report ID: 7993
- Published Date: Aug 04, 2025
- Report Format: PDF, PPT
- Get detailed insights on specific segments/region
- Inquire about report customization for your industry
- Learn about our special pricing for startups
- Request a demo of the report’s key findings
- Understand the report’s forecasting methodology
- Inquire about post-purchase support and updates
- Ask About Company-Level Intelligence Additions
Have specific data needs or budget constraints?
Inquiry Before BuyingFrequently Asked Questions (FAQ)
Laboratory Centrifuge Market Report Scope
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Connect with our Expert
